You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,987,326

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,987,326

Title:	Klotho protein and related compounds for the treatment and diagnosis of cancer
Abstract:	Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.
Inventor(s):	Koeffler; H. Phillip (Los Angeles, CA), Wolf; Ido (Or Yehuda, IL), Rubinek; Tamar (Or Yehuda, IL), Kaufman; Bella (Kiryat Ono, IL), Abramovitch; Lilach (Kfar Saba, IL)
Assignee:	Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA)
Application Number:	13/419,610
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,987,326
Patent Claims:	1. A method comprising: administering to a subject with cancer a pharmaceutically effective amount of a composition comprising: (a) a soluble polypeptide consisting of an extracellular domain of a klotho protein, wherein the klotho protein is encoded by one of SEQ ID NOS: 1, 2, 3, 4, 5, 11, 12, 13, 14 or 15; or (b) a soluble polypeptide consisting of an amino acid sequence selected from the group consisting of residues 31 to 982 of SEQ ID NO: 1, residues 34 to 1012 of SEQ ID NO: 1, residues 34 to 549 of SEQ ID NO: 2, residues 31 to 982 of SEQ ID NO: 3, and residues 36 to 1014 of SEQ ID NO: 3; or (c) a soluble polypeptide consisting of an amino acid sequence having at least 80% homology to a polypeptide defined in (a) or (b); and a pharmaceutically-acceptable carrier. 2. The method of claim 1, wherein the cancer is selected from the group consisting of colon cancer, prostate cancer, lung cancer, cervical cancer, ovarian cancer, breast cancer and pancreatic cancer. 3. The method of claim 2, wherein the cancer is breast cancer. 4. The method of claim 2, wherein the cancer is pancreatic cancer. 5. The method of claim 1, wherein a degree of said homology is at least 90%. 6. The method of claim 5, wherein said degree of homology is at least 95%. 7. The method of claim 6, wherein said degree of homology is at least 98%. 8. The method of claim 1, wherein the composition further comprises one or more chemotherapeutic agents. 9. The method of claim 8, wherein the composition comprises one or more chemotherapeutic agents selected from the group consisting of alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, hormone receptor modulators, and hormone level modulators. 10. The method of claim 8, wherein the composition comprises one or more chemotherapeutic agents selected from the group consisting of busulfan, carboplatin, carmustine, cisplatin, chloroambucil, cyclophosphamide, dacarbazine, hexamethylmelamine, ifosfamide, mechlorethamine, melphalan, oxoplatin, streptozocin, temozolomide, thiotepa, uramustine, azathioprine, capecitabine, carmofur, cladribine, clofarabine, cytarabine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, premetrexed, raltitrexed, tegafur, tioguanine, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone valrubicin, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, amsacrine, etoposide, etoposide phosphate, irinotecan, teniposide, topotecan, tamoxifen, faslodex, letrozole, anastrazole aromasin, dactinomycin, trastuzumab, lapatinib, bevacizumab, cetuximab, panitumumab, erlotinib, and sunitinib.

Details for Patent 9,987,326

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2039-02-26
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.